Company Encyclopedia
View More
name
C&Y Pharmaceutical
300254.SZ
ShanXi C&Y Pharmaceutical Group Co.,LTD. engages in the research, development, production, and sale of medicine and health food products. It provides anti-infective drugs, anti-allergic drugs, respiratory drugs, urinary system drugs, kidney disease drugs, children's drugs, cardiovascular and cerebrovascular drugs, anti-depressants, medicines, pharmaceutical raw materials, and intermediates, commerce, etc. The company’s product portfolio includes Fosfomycin tromethamine powder, Ebastine tablets, Tamsulosin hydrochloride sustained release capsules, Cinacalcet hydrochloride tablets, Apixaban tablets, Rivaroxaban tablets, Fluoxetine hydrochloride capsules, Ambroxol hydrochloride dispersible tablets, Montmorillonite powder, Varenicline tartrate tablets, Vitamin AD drops, and Baoling Yunbao oral liquid, as well as salt acid glucosamine raw material product.
3.105 T
300254.SZMarket value -Rank by Market Cap -/-

Financial Score

25/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking169/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE4.32%C
    • Profit Margin2.40%C
    • Gross Margin65.60%A
  • Growth ScoreD
    • Revenue YoY1.56%C
    • Net Profit YoY-75.48%E
    • Total Assets YoY1.49%C
    • Net Assets YoY-32.30%E
  • Cash ScoreB
    • Cash Flow Margin4170.36%A
    • OCF YoY1.56%C
  • Operating ScoreC
    • Turnover0.55C
  • Debt ScoreD
    • Gearing Ratio62.76%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    C&Y Pharmaceutical: Net profit in the third quarter was 21.9466 million yuan, a year-on-year increase of 106.06%

    C&Y Pharmaceutical announced that the revenue for the third quarter was 238 million yuan, a year-on-year increase of 14.82%; the net profit was 21.9466 million yuan, a year-on-year increase of 106.06%. The revenue for the first three quarters was 611 million yuan, a year-on-year increase of 0.44%; the net profit was 22.3274 million yuan, a year-on-year decrease of 49.43%

    Zhitong·
    SZ
    300254
    +0.20%
    Zhitong·
    SZ
    300254
    +0.20%

    C&Y Pharmaceutical shareholder Weng Zhanguo plans to reduce his holdings by no more than 3%

    According to the Zhitong Finance APP, C&Y Pharmaceutical announced that its shareholder Weng Zhanguo plans to reduce his holdings in the company by no more than 7.6831 million shares (not exceeding 3% of the company's total share capital) through centralized bidding and block trading from November 13, 2025, to February 12, 2026

    Zhitong·
    SZ
    300254
    +0.20%
    Zhitong·
    SZ
    300254
    +0.20%

    C&Y Pharmaceutical: Launching a financing lease sale-leaseback business not exceeding 50 million yuan

    On the evening of September 15th, C&Y Pharmaceutical announced that the company will carry out financing lease sale-leaseback business, using part of its fixed assets to apply for financing of no more than 50 million yuan from Ping An Dian Chuang International Financial Leasing Co., Ltd., with a term of 2 and a half years

    Zhitong·
    SZ
    300254
    +0.20%
    Zhitong·
    SZ
    300254
    +0.20%

    The hepatitis concept sector has seen a short-term surge

    The hepatitis concept sector saw a short-term surge, with KHB hitting the limit up, and C&Y Pharmaceutical, BIOCAUSE HEILEN PHARMA, DAJY, Yatai pharm, and Honz all rising

    Zhitong·
    SZ
    300086
    +7.20%
    SZ
    002022
    0.00%
    SZ
    300254
    +0.20%
    Zhitong·
    SZ
    300086
    +7.20%
    SZ
    002022
    0.00%
    SZ
    300254
    +0.20%

    C&Y Pharmaceutical plans to launch a restricted stock incentive plan of no more than 9.15 million shares

    According to the Zhitong Finance APP, C&Y Pharmaceutical disclosed the draft of the 2025 Restricted Stock Incentive Plan, which proposes to grant a total of no more than 9.15 million restricted shares to the incentive recipients, accounting for 3.68% of the company's total share capital at the time of the announcement of this incentive plan draft. Among them, 7.95 million shares will be granted in the first grant, with a total of 171 incentive recipients, and the grant price (including reserves) is set at 5.60 yuan/share

    Zhitong·
    SZ
    300254
    +0.20%
    Zhitong·
    SZ
    300254
    +0.20%
    © 2025 Longbridge｜Disclaimer